OS Therapies
Targeting Osteosarcoma, Breast Cancer and other Solid Tumors to prevent HER2-metastasis and destroy solid tumors.
Targeting Osteosarcoma, Breast Cancer and other Solid Tumors to prevent HER2-metastasis and destroy solid tumors.
OS Therapies is a clinical stage research company founded in 2017, with a focus on therapeutic treatments for Osteosarcoma and other solid tumors. The company's slogan, "Targeting Osteosarcoma and other Solid Tumors to prevent metastasis and destroy solid tumors," encapsulates its mission. OS Therapies employs two platform technologies, OST-HER2 to prevent metastasis and OST-tADC to debulk solid tumors. The company operates within the Health Care and Pharmaceutical industries, with its headquarters located in the United States. In its latest funding round, OS Therapies secured a $1.00M investment through Debt Financing on 16 July 2021. The investors in the last round were not disclosed. OS Therapies' focus on addressing critical unmet needs in oncology, combined with its proprietary technologies, positions the company as a compelling player in the fight against solid tumors.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Debt Financing | $1.00M | - | 16 Jul 2021 | |
| Series A | $6.00M | 3 |
|
20 Apr 2021 |
No recent news or press coverage available for OS Therapies.
We care about your data, and we'd love to use cookies make your experience better.
